Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The chat is scheduled for September 16 at 8:30 a.m. EDT and will be webcast live, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website. The full press release can be accessed at https://ibn.fm/r0jfC.
The invitation to present at a major healthcare investor conference underscores growing institutional interest in Helus Pharma's novel approach to mental health treatment. The company is developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma seeks to improve the treatment landscape by providing durable improvements in mental health.
Helus Pharma's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation is significant because it expedites the development and review of drugs that may offer substantial improvements over existing therapies. The company is also developing HLP004, another proprietary NSA, in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma maintains an extensive research portfolio of investigational NSAs.
The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information and company updates, visit www.helus.com. Helus Pharma is a trademark of Cybin Corp. Investors can find the latest news and updates relating to HELP in the company's newsroom at https://ibn.fm/HELP.
The fireside chat at the Morgan Stanley conference matters because it provides a platform for Helus Pharma to communicate its clinical progress and strategic vision directly to influential investors, analysts, and healthcare experts. Positive reception could enhance the company's visibility, potentially attracting investment needed to advance its pipeline. Moreover, with depression and anxiety affecting millions worldwide, Helus Pharma's NSA programs represent a promising new avenue for treatment. If successful, these therapies could significantly improve outcomes for patients who do not respond adequately to current medications. The Breakthrough Therapy Designation for HLP003 further validates the potential of the company's approach and may accelerate its path to market. As the mental health crisis continues to grow, innovative solutions like those from Helus Pharma are increasingly important, making this presentation a key event for stakeholders to watch.
